Does Dr. LAMA ABDELNOUR have financial conflicts of interest?

Dr. LAMA ABDELNOUR (MD) has received a total of $18,245 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $18,245 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. LAMA ABDELNOUR?

According to CMS Open Payments data, Dr. LAMA ABDELNOUR received funding from TRAVERE THERAPEUTICS ($8,031), NOVARTIS PHARMACEUTICALS CORPORATION ($6,643), and CALLIDITAS THERAPEUTICS US ($3,079).

Does Dr. LAMA ABDELNOUR receive research grants or speaking fees?

Dr. LAMA ABDELNOUR has received $18,245 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. LAMA ABDELNOUR

MDReal-Time Hydrated

Specialty: Internal Medicine, Nephrology

Practice Location: LOS ANGELES, CA 90095

NPI Number: 1477817542

LIFETIME INDUSTRY VALUE

$18,245

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDELNOUR is a verified Internal Medicine, Nephrology practitioner based in LOS ANGELES, CA.

Between 2021 and 2024, Dr. ABDELNOUR had an overall industry promotional and research financial footprint of $18,245 as recorded in the federal CMS Open Payments database.

$18,245 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDELNOUR's primary funding source is TRAVERE THERAPEUTICS, which accounts for $8,031 (representing 44% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

TRAVERE THERAPEUTICS

Rank 1

$8,031

44%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$6,643

36.4%

CALLIDITAS THERAPEUTICS US

Rank 3

$3,079

16.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.